SCHEMBL7064871

SCHEMBL7064871

COCCO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC(=O)c3ccccc3)ncnc21

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 5/20 0.56
LMNA P02545 2/20 0.55
SLC29A1 Q99808 2/20 0.55
ALDH1A1 P00352 1/20 0.55
GLA P06280 1/20 0.55
PMP22 Q01453 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
NPC1 O15118 1/20 0.55
NPY1R P25929 1/20 0.55
HTT P42858 1/20 0.55
NPY2R P49146 1/20 0.55
RAB9A P51151 1/20 0.55
RXFP1 Q9HBX9 1/20 0.55
CYP1A2 P05177 1/20 0.55
TSHR P16473 1/20 0.55
NFKB1 P19838 1/20 0.55
MAPK1 P28482 1/20 0.55
CYP2C19 P33261 1/20 0.55
THPO P40225 1/20 0.55
ADORA3 P0DMS8 4/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19407591 1.00 ADORA1 (0.56) ADORA1LMNASLC29A1ALDH1A1GLA
SCHEMBL7064875 1.00 ADORA1 (0.56) ADORA1LMNASLC29A1ALDH1A1GLA
SCHEMBL38653713 1.00 ADORA1 (0.56) ADORA1LMNASLC29A1ALDH1A1GLA
SCHEMBL16940281 0.93 PRMT6 (0.51) ADORA1ADORA3
SCHEMBL6897956 0.93 ADORA1 (0.56) ADORA1LMNASLC29A1ALDH1A1GLA
SCHEMBL25966151 0.93 PRMT6 (0.51) ADORA1ADORA3
SCHEMBL19399423 0.93 PRMT6 (0.51) ADORA1ADORA3
SCHEMBL7066396 0.93 ADORA1 (0.54) ADORA1LMNASLC29A1ALDH1A1GLA
SCHEMBL7066397 0.93 ADORA1 (0.54) ADORA1LMNASLC29A1ALDH1A1GLA
SCHEMBL6899424 0.92 ADORA1 (0.56) ADORA1LMNASLC29A1ALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6624294-B2 Dissolving nucleoside in solvent to form a solution; cooling; treating with base; warming; reacting with ester to effect alkylation of 2' position of a 2',3'-dihydroxy sugar moiety of a nucleoside ISIS PHARMACEUTICALS, INC. 2003-09-23 US disclosed
US-20030078415-A1 Regioselective synthesis of 2'-O-modified nucleosides IONIS PHARMACEUTICALS, INC. 2003-04-24 US disclosed
US-6403779-B1 DISSOLVING NUCLEOSIDE IN APROTIC SOLVENT, COOLING, TREATING WITH BASE, WARMING MIXTURE, COOLING, REACTING WITH REACTIVE ESTER TO EFFECT ALKYLATION ISIS PHARMACEUTICALS, INC. 2002-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078415-A1 Regioselective synthesis of 2'-O-modified nucleosides NSUN2, NT5C3B, RNGTT ADORA1 1499/4885LMNA 496/4885SLC29A1 201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.